Full Press Release Details
Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note
WA - April 9, 2026 - OSR Holdings, Inc. (NASDAQ: OSRH) ("OSR Holdings" or the "Company")
today announced a strategic transaction for capital structure optimization with White Lion GBM Innovation Fund ("White Lion"),
centered on the retirement of approximately $2.02 million of warrant overhang.
of $2.02 Million Warrant Overhang
the transaction, OSR Holdings has retired approximately $2.02 million of outstanding warrants by consolidating them into a newly issued
convertible promissory note.
enables OSR Holdings to eliminate a substantial source of potential dilution at a significant discount to the prior overhang value, representing
a highly efficient balance sheet optimization.
Conversion Price at $1.00 per Share
note is structured with a fixed conversion price of $1.00 per share, representing approximately a 100% premium to the Company's
most recent closing price of approximately $0.49 on April 8, 2026.
Conversion Restriction
was issued as a private placement without a registration statement:
transaction is fundamentally about removing structural overhang and strengthening our equity story," said Peter Hwang, CEO
of OSR Holdings. "By retiring over $2 million in warrant overhang into a tightly structured instrument, we are meaningfully
cleaning up our cap table. Furthermore, the $1.00 conversion price and six-month restriction demonstrate a shared
commitment by our investor to stabilizing our valuation as we focus on regaining NASDAQ minimum bid compliance."
believes this transaction represents a meaningful step in optimizing its capital structure, removing technical barriers to equity performance,
and securing near-term capital to advance its strategic priorities across its immunotherapy, degenerative disease, and medtech platforms.
regarding this transaction will be included in the Company's filings with the U.S. Securities and Exchange Commission.
White Lion GBM Innovation Fund
Lion GBM Innovation Fund, one of Innovate GBM's core sponsors, focuses on strategic funding opportunities in glioblastoma drug development.
The Innovation Fund leverages the ecosystem curated by Innovate GBM to gain insights from the GBM community-including neuro-oncologists,
scientists, and patient advocacy groups-to guide capital allocation toward the most impactful opportunities.
About OSR Holdings, Inc.
OSR Holdings, Inc. (NASDAQ: OSRH)
is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries,
OSRH engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more
release contains forward-looking statements within the meaning of applicable U.S. securities laws, including statements regarding the
Company's capital structure, liquidity, and expected benefits of the financing. These statements are subject to risks and uncertainties
that could cause actual results to differ materially, including those described in the Company's filings with the U.S. Securities
and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, except as required by law.